Izalontamab brengitecan

SystImmune will present updated safety and efficacy data for izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjugate, in locally advanced or metastatic breast cancer at ESMO Breast 2025 on May 16.

Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.

A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing approximately 30 drug candidates for nasopharyngeal cancer, signaling significant industry investment in this therapeutic area.

Datopotamab deruxtecan (Dato-DXd) shows promise in EGFR-mutated NSCLC, with a new BLA submitted for accelerated approval after a previous withdrawal based on the TROPION-Lung01 trial.

BL-B01D1, a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC), has received breakthrough therapy designation from China's NMPA for recurrent small cell lung cancer. This marks the drug's fifth breakthrough designation, highlighting its potential across multiple cancer indications including lung, breast, and nasopharyngeal cancers.